Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy
Zixuan Ye,Lizhen Liang,Huazhen Lu,Yan Shen,Wenwu Zhou,Yanan Li
DOI: https://doi.org/10.2147/IJN.S329855
IF: 7.033
2021-12-14
International Journal of Nanomedicine
Abstract:Zixuan Ye, 1, &ast Lizhen Liang, 1, &ast Huazhen Lu, 1 Yan Shen, 2 Wenwu Zhou, 3 Yanan Li 1 1 School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, People's Republic of China; 2 State Key Laboratory of Natural Medicines, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China; 3 National Experimental Teaching Demonstration Center of Pharmacy, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yanan Li School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, People's Republic of China Tel +8615051850598 Email Wenwu Zhou National Experimental Teaching Demonstration Center of Pharmacy, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China Email Bacteria and their derivatives (membrane vesicles, MVs) exhibit great advantages for targeting hypoxic tumor cores, strong penetration ability and activating immune responses, holding great potential as auspicious candidates for therapeutic and drug-delivery applications. However, the safety issues and low therapeutic efficiency by single administration still need to be solved. To further optimize their performance and to utilize their natural abilities, scientists have strived to modify bacteria with new moieties on their surface while preserving their advantages. The aim of this review is to give a comprehensive overview of a non-genetic engineering modification strategy that can be used to optimize the bacteria with nanomaterials and the design strategy that can be used to optimize MVs for better targeted therapy. Here, the advantages and disadvantages of these processes and their applicability for the development of bacteria-related delivery system as antitumor therapeutic agents are discussed. The prospect and the challenges of the above targeted delivery system are also proposed. Keywords: bacteria, nanomaterial, targeted delivery, immune response, membrane vesicles Due to the abnormal hyperplasia of the vascular system in tumor tissue, a specific anaerobic, acidic microenvironment is formed in tumors. Over the past decades, targeting delivery of therapeutic drugs into cancer with reduced side effects still remains a challenge in cancer therapy. Researchers have made a series of attempts in the drug delivery systems; various viral vectors (e.g., adenovirus, adeno-associated virus), abiotic carriers (e.g., micelles, liposomes, carbon materials, inorganic structures, self-assembled peptide and protein nanostructures) and cell carriers (e.g., bacteria, red blood cells) were developed to achieve active or passive targeting to tumor tissue. 1–4 Among the cell carriers, bacteria have been explored in cancer therapy for more than a century, including Salmonella, Listeria monocytogenes and Bifidobacterium . Compared with other synthetic carriers, bacteria exhibit multiple advantages, such as (1) the unique ability to preferentially penetrate and colonize anaerobic tumors by an aerotaxis or chemotaxis pathway; 5 (2) their intrinsic genetic system, which is easily engineered to deliver antitumor agents such as genes or proteins; 6 and (3) their own immune-stimulating activity, 7 which allows them to act as adjuvants in tumor immunotherapy. Despite the above advantages, several challenges in bacteria-mediated delivery still exist, such as (1) the risks and safety of bacteria and their derivatives; 8–10 (2) the active targeting efficiency remains to be enhanced; and (3) expanding the types of drug carried by bacteria. 11 To address these concerns, a nanotechnology-employed bacteria-based delivery strategy is considered to be an effective strategy to improve bacteria-mediated tumor therapy. In this review, the current developments and their deficiencies of bacteria as therapeutic agents or delivery system are first introduced. Then, we focus on the design strategy of a nanotechnology-employed bacteria-based drug delivery system (e.g., bacteria-derived nano-hybrid, bacteria-derived outer membrane vesicles based nano-platforms) and highlight the interaction between bacteria and nanomaterials and the modification strategies to complement or enhance their therapeutic applicability in cancer field. This review can provide more perspectives for the practical medicinal application for a nanotechnology-employed bacteria-based drug delivery system in the future. In the design of a bacter -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology